Witnessing the stock’s movement on the chart, on Wednesday, Novavax, Inc (NASDAQ: NVAX) had a quiet start as it plunged -4.11% to $8.63, before settling in for the price of $9.00 at the close. Taking a more long-term approach, NVAX posted a 52-week range of $3.53-$23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 513.29%. Meanwhile, its Annual Earning per share during the time was 11.55%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 73.63%. This publicly-traded company’s shares outstanding now amounts to $160.15 million, simultaneously with a float of $153.00 million. The organization now has a market capitalization sitting at $1.38 billion. At the time of writing, stock’s 50-day Moving Average stood at $9.37, while the 200-day Moving Average is $10.48.
Novavax, Inc (NVAX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Novavax, Inc’s current insider ownership accounts for 4.49%, in contrast to 58.98% institutional ownership.
Novavax, Inc (NVAX) Earnings and Revenue Records
Novavax, Inc’s EPS increase for this current 12-month fiscal period is 73.63% and is forecasted to reach 0.10 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 37.90% through the next 5 years, which can be compared against the 11.55% growth it accomplished over the previous five years trading on the market.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Let’s observe the current performance indicators for Novavax, Inc (NVAX). It’s Quick Ratio in the last reported quarter now stands at 0.93. The Stock has managed to achieve an average true range (ATR) of 0.57. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.56.
In the same vein, NVAX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.26, a figure that is expected to reach -0.60 in the next quarter, and analysts are predicting that it will be 0.10 at the market close of one year from today.
Technical Analysis of Novavax, Inc (NVAX)
Going through the that latest performance of [Novavax, Inc, NVAX]. Its last 5-days volume of 3.49 million was inferior to the volume of 9.25 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 46.21% While, its Average True Range was 0.54.
Raw Stochastic average of Novavax, Inc (NVAX) in the period of the previous 100 days is set at 21.64%, which indicates a major fall in contrast to 30.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 46.78% that was lower than 92.73% volatility it exhibited in the past 100-days period.
